How are KURA strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the KURA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 83.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$370.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a KURA strangle?

The breakeven for the KURA strangle priced on this page is roughly $5.30 and $13.70 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KURA market-implied 1-standard-deviation expected move is approximately 23.91%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current KURA implied volatility affect this strangle?

KURA ATM IV is at 83.40% with IV rank near 9.82%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

KURA Strangle Strategy

KURA (Kura Oncology, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

KURA (Kura Oncology, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $841.5M, a beta of 0.32 versus the broader market, a 52-week range of 5.45-12.49, average daily share volume of 1.4M, a public-listing history dating back to 2015, approximately 192 full-time employees. These structural characteristics shape how KURA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.32 indicates KURA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on KURA?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current KURA snapshot

As of May 13, 2026, spot at $9.46, ATM IV 83.40%, IV rank 9.82%, expected move 23.91%. The strangle on KURA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this strangle structure on KURA specifically: KURA IV at 83.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a KURA strangle, with a market-implied 1-standard-deviation move of approximately 23.91% (roughly $2.26 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KURA expiries trade a higher absolute premium for lower per-day decay. Position sizing on KURA should anchor to the underlying notional of $9.46 per share and to the trader's directional view on KURA stock.

KURA strangle setup

The KURA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KURA near $9.46, the first option leg uses a $10.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KURA chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KURA shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$10.00	$1.10
Buy 1	Put	$9.00	$2.60

KURA strangle risk and reward

Net Premium / Debit: -$370.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$370.00
Breakeven(s): $5.30, $13.70
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

KURA strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on KURA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$529.00
$2.10	-77.8%	+$319.94
$4.19	-55.7%	+$110.89
$6.28	-33.6%	-$98.17
$8.37	-11.5%	-$307.22
$10.46	+10.6%	-$323.72
$12.55	+32.7%	-$114.67
$14.64	+54.8%	+$94.39
$16.73	+76.9%	+$303.44
$18.82	+99.0%	+$512.50

When traders use strangle on KURA

Strangles on KURA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the KURA chain.

KURA thesis for this strangle

The market-implied 1-standard-deviation range for KURA extends from approximately $7.20 on the downside to $11.72 on the upside. A KURA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current KURA IV rank near 9.82% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on KURA at 83.40%. As a Healthcare name, KURA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KURA-specific events.

KURA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KURA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KURA alongside the broader basket even when KURA-specific fundamentals are unchanged. Always rebuild the position from current KURA chain quotes before placing a trade.

Frequently asked questions

What is a strangle on KURA?: A strangle on KURA is the strangle strategy applied to KURA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With KURA stock trading near $9.46, the strikes shown on this page are snapped to the nearest listed KURA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are KURA strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the KURA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 83.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$370.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a KURA strangle?: The breakeven for the KURA strangle priced on this page is roughly $5.30 and $13.70 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KURA market-implied 1-standard-deviation expected move is approximately 23.91%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on KURA?: Strangles on KURA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the KURA chain.
How does current KURA implied volatility affect this strangle?: KURA ATM IV is at 83.40% with IV rank near 9.82%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.